Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Radiology Business
Epsilon Health Launches With $28M to Build 'AI-Native' Imaging Practice
Epsilon Health has exited stealth mode, raising nearly $28M to launch an 'AI-native' radiology imaging group aimed at addressing the U.S. radiologist shortage.
•Radiology Business
UCLA Review Evaluates Breast AI for Early Cancer Detection
A UCLA-led review analyzes current evidence for AI tools in screening mammography, focusing on their capability to detect interval cancers.
•Radiology Business
Harrison.ai Restructures and Launches U.S. AI-Enabled Teleradiology Venture
Harrison.ai lays off staff amid major restructuring and launches Frontier Radiology, an AI-powered U.S. teleradiology business.